Special Counsel Finds No Wrongdoing in Whistleblower Probe
This article was originally published in The Gray Sheet
A three-year investigation into whistleblower allegations that FDA had improperly cleared several devices has ended with a Special Counsel finding that the claims were unfounded.
You may also be interested in...
Multiple investigations and lawsuits have opened in response to the matter, with more potentially to come. Some worry the intensifying issue has serious implications for the quality of the device center’s output.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
With the pre-GDUFA backlog largely acted upon, the FDA expects ANDA approvals to decrease, but supplement actions to increase in FY 2020 and FY 2021.